Skip to main content
SpringerLink
Log in

Expression of the von Hippel-Lindau tumor suppressor gene in nonneoplastic and neoplastic lesions of the thyroid

  • Clinical Research
  • Published:
Endocrine Pathology Aims and scope Submit manuscript

Abstract

Alterations of the von Hippel-Lindau (VHL) gene, which is supposed to act as a tumor suppressor gene, can cause hereditary tumors associated with the VHL syndrome and are found in different sporadic cancers as well. While VHL protein is distinctly detectable in thyroid follicles, so far its expression in nonneoplastic and neoplastic lesions of the thyroid has not been investigated comprehensively. To illuminate the role of VHL for thyroid tumorigenesis, we investigated 12 follicular adenomas; 22 follicular carcinomas; 11 papillary carcinomas; 6 poorly differentiated carcinomas (PDTCs); 9 undifferentiated carcinomas (UTCs); 8 medullary carcinomas; 13 cases with nonneoplastic as well as normal thyroid tissue of 10 patients with antibodies against VHL, vascular endothelial growth factor (VEGF); and the proliferation marker MIB1 immunohistochemically; and selected cases by Western blot analysis. VHL was clearly expressed in nonneoplastic lesions and differentiated tumors derived from follicular epithelium, diminished in PDTCs and very weakly or not detectable in UTCs (p=0.001), nonneoplastic, and neoplastic C-cells. Although slightly increased in certain differentiated tumors, VEGF was found to be reduced in UTCs as well. In summary, VHL is expressed differently in nonneoplastic and neoplastic lesions of the thyroid in proportion to the level of differentiation. VHL gene alterations appear to be a late event in tumorigenesis of the thyroid and a reduction in VHL protein expression is associated with a loss of differentiation and increased aggressiveness in thyroid tumors. There is no apparent inverse correlation between VHL and VEGF expression as described for other sporadic carcinomas. Therefore, the role of VHL for angiogenesis and the molecular basis of the inactivation of VHL in thyroid tumors remains to be elucidated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lindor NM, Green MH. The concise handbook of family cancer syndromes. J Natl Cancer Inst 90:1039–1071, 1998.

    Article  PubMed  CAS  Google Scholar 

  2. Kaelin WG, Maher ER. The VHL tumor-suppressor gene paradigm. Trends Genet 14:423–426, 1998.

    Article  PubMed  CAS  Google Scholar 

  3. Webster AR, Richards FM, MacRonald FE, More AT, Maher ER. An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects. Am J Hum Genetics 63:1025–1035, 1998.

    Article  CAS  Google Scholar 

  4. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317–1320, 1993.

    Article  PubMed  CAS  Google Scholar 

  5. Los M, Jansen GH, Kaelin WG, Lips CJM, Blijham GH, Voest EE. Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest 75:231–238, 1996.

    PubMed  CAS  Google Scholar 

  6. Corless CL, Kibel AS, Iliopoulos O, Kaelin WG. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol 28:459–464, 1997.

    Article  PubMed  CAS  Google Scholar 

  7. Kaelin WG, Iliopoulos O, Lonergan KM, Ohh M. Functions of the von Hippel-Lindau tumour suppressor protein. J Intern Med 243:535–539, 1998.

    Article  PubMed  CAS  Google Scholar 

  8. Scheonfeld A, Davidowitz EJ, Burk JD. A second major native von Hippel-Lindau gene product, initiated from internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci USA 95:8817–8822, 1998.

    Article  Google Scholar 

  9. Iliopoulos O, Ohh M, Kaelin WG. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA 95:11,661–11,666, 1998.

    Article  CAS  Google Scholar 

  10. Sakashita N, Takeya M, Kishida T, Stackhouse TM, Zbar B, Takahashi K. Expression of von Hippel-Lindau protein in normal and pathological human tissues. Histochem J 31:133–144, 1999.

    Article  PubMed  CAS  Google Scholar 

  11. Vortmeyer AO, Lubensky IA, Fogt F, Linehan WM, Khettry U, Zhuang Z. Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas. Am J Pathol 151:951–956, 1997.

    PubMed  CAS  Google Scholar 

  12. Iliopoulos O, Kaelin WG. The molecular basis of von Hippel-Lindau disease. Mol Med 5:289–293, 1997.

    Google Scholar 

  13. Sekido Y, Bader S, Latif F, Gnarra JR, Gazdar AF, Linehan WM, Zbar B, Lerman MI, Minna JD. Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. Oncogene 9:1599–1604, 1994.

    PubMed  CAS  Google Scholar 

  14. Kanno H, Shuin T, Kondo K, Yamamoto I, Ito S, Shinonaga M, Yoshida M, Yao M. Somatic mutations of the von Hippel-Lindau tumor suppressor gene and loss of heterozygosity on chromosome 3p in human glial tumors. Cancer Res 57:1035–1038, 1997.

    PubMed  CAS  Google Scholar 

  15. Fogt F, Vortmeyer AO, Stolte M, Mueller E, Mueller J, Noffsinger A, Poremba C, Zhuang Z. Loss of heterozygosity of the von Hippel Lindau gene locus in polypoid dysplasia but not flat dysplasia in ulcerative colitis or sporadic adenomas. Hum Pathol 29:961–964, 1998.

    Article  PubMed  CAS  Google Scholar 

  16. Shiao YH, Rice JM, Anderson LM, Diwan BA, Hard GC. Von Hippel-Lindau gene mutations in N-nitrosodimethylamine-induced rat renal epithelial tumors. J Natl Cancer Inst 90:1720–1723, 1998.

    Article  PubMed  CAS  Google Scholar 

  17. Mukhopadhyay D, Knebelmann B, Cohen HAT, Ananth S, Sukhatme VP. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 17:5629–5639, 1997.

    PubMed  CAS  Google Scholar 

  18. Lazzereschi D, Mincione G, Coppa A, Ranieri A, Turco A, Baccheschi G, Pelicano S, Colletta G. Oncogenes and antioncogenes involved in human thyroid carcinogenesis. J Exp Clin Cancer Res 16:325–332, 1997.

    PubMed  CAS  Google Scholar 

  19. Rosai J, Carcangui ML, DeLellis RA. Poorly differentiated carcinoma. In: Rosai J, Sobin LH, eds. Tumors of the thyroid gland: atlas of tumor pathology. Third series, fascicle 5. Washington, DC: Armed Forces Institute of Pathology, 1992; 123–133.

    Google Scholar 

  20. Remmele W, Hildebrand U, Hienz H, Klein PJ, Vierbuchen M, Behnken LJ, Heicke B, Scheidt E. Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch 409:127–147, 1986.

    Article  CAS  Google Scholar 

  21. Fonseca E, Soares P, Rossi S, Sobrinho-Simoes M. Prognostic factors in thyroid carcinomas. Verh Dtsch Ges Pathol 81:82–96, 1997.

    PubMed  CAS  Google Scholar 

  22. Lieubeau-Teillet B, Rak J, Jothy S, Iliopoulos O, Kaelin W, Kerbel RS. Von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res 58:4957–4962, 1998.

    PubMed  CAS  Google Scholar 

  23. Gilcrease MZ, Schmidt L, Zbar B, Truong L, Rutledge M, Wheeler TM. Somatic von Hippel-Lindau mutation in clear cell papillary cystadenoma of the epididymis. Hum Pathol 26:1341–1346, 1995.

    Article  PubMed  CAS  Google Scholar 

  24. Lee JY, Dong SM, Park WS, Yoo NJ, Kim CS, Jang JJ, Chi JG, Zbar B, Lubensky IA, Linehan WM, Vortmeyer AO, Zhuang Z. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res 58:504–508, 1998.

    PubMed  CAS  Google Scholar 

  25. Van der Harst E, de Krijger RR, Dinjens WN, Weeks LE, Bonjer HJ, Bruining HA, Lamberts SW, Koper JW. Germline mutations in the vhl gene in patients presenting with phaeochromocytomas. Int J Cancer 77:337–340, 1998.

    Article  PubMed  Google Scholar 

  26. Lubensky IA, Gnarra JR, Bertheau P, Walther MM, Linehan WM, Zhuang Z. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 149:2089–2094, 1996.

    PubMed  CAS  Google Scholar 

  27. Herman JG, Latif F, Wenig Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91:9700–9704, 1994.

    Article  PubMed  CAS  Google Scholar 

  28. Grebe SK, McIver B, Hay ID Wu PS, Maciel LM, Drabkin HA, Goellner JR, Grant CS, Jenkins RB, Eberhardt NL. Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma. J Clin Endocrinol Metab 82:3684–3691, 1997.

    Article  PubMed  CAS  Google Scholar 

  29. Flamme I, Krieg M, Plate KH. Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2alpha. Am J Pathol 153:25–29, 1998.

    PubMed  CAS  Google Scholar 

  30. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 56:2013–2016, 1996.

    PubMed  CAS  Google Scholar 

  31. Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG, Garcia YK, Min YD, Grossman RF, Siperstein AE, Clark OH. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 82:3741–3747, 1997.

    Article  PubMed  CAS  Google Scholar 

  32. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, Fedele M, Ippolito P, Chiappetta G, Botti G, Fusco A, Persico AG. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11:1569–1579, 1995.

    PubMed  CAS  Google Scholar 

  33. Viglietto G, Romano A, Manzo G, Chiappetta G, Paoletti I, Califano D, Galati MG, Mauriello V, Bruni P, Lago CT, Fusco A, Persico MG. Upregulation of the angiogenic factors P1GF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene 15:2687–2698, 1997.

    Article  PubMed  CAS  Google Scholar 

  34. Pal S, Claffey KP, Dvorak HF, Mukhopadhyay D. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem 272:27,509–27,512, 1997.

    Article  CAS  Google Scholar 

  35. Knebelmann B, Ananth S, Cohen HT, Sukhatme VP. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 58:226–231, 1998.

    PubMed  CAS  Google Scholar 

  36. Los M, Zeamari S, Foekens JA, Gebbink MFBG, Voest EE. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene. Cancer Res 59:4440–4445, 1999.

    PubMed  CAS  Google Scholar 

  37. Iwai K, Yamanaka K, Kamura T, Minota N, Conaway RC, Conaway JW, Klausner RD, Pause A. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. PNAS 96:12,436–12,441, 1999.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Surgery, Martin-Luther-University of Halle-Wittenberg, Halle, Germany

    Henning Dralle

  2. Institute of Pathology, Martin-Luther-University of Halle-Wittenberg, Magdeburger Str. 14, D-06097, Hallc, Germany

    Raoul Hinze MD, Carsten Boltze MD, Axel Meye PhD, Hans-Jürgen Holzhausen MD & Friedrich-Wilhelm Rath MD

Authors
  1. Raoul Hinze MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carsten Boltze MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Axel Meye PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hans-Jürgen Holzhausen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Henning Dralle
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Friedrich-Wilhelm Rath MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raoul Hinze MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hinze, R., Boltze, C., Meye, A. et al. Expression of the von Hippel-Lindau tumor suppressor gene in nonneoplastic and neoplastic lesions of the thyroid. Endocr Pathol 11, 145–155 (2000). https://doi.org/10.1385/EP:11:2:145

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/EP:11:2:145

Key Words

Search

Navigation